RT Journal Article
SR Electronic
T1 Alzheimer’s disease clinical decision points for two plasma p-tau217 laboratory developed tests in neuropathology confirmed samples
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.27.24310872
DO 10.1101/2024.07.27.24310872
A1 Mammel, Anna E.
A1 Hsiung, Ging-Yuek Robin
A1 Mousavi, Ali
A1 Hallett, Kelsey
A1 Mackenzie, Ian R.
A1 Hirsch-Reinshagen, Veronica
A1 Biehl, Don
A1 Gill, Pradip
A1 Encarnacion, Mary
A1 Frykman, Hans
YR 2024
UL http://medrxiv.org/content/early/2024/07/29/2024.07.27.24310872.abstract
AB INTRODUCTION We evaluated the diagnostic performance of two commercial plasma p-tau217 immunoassays compared to CSF testing and neuropathology.METHODS 170 plasma samples from University of British Columbia Hospital Clinic for Alzheimer’s (AD) and Related Disorders were analyzed for p-tau217 using Fujirebio and ALZpath assays. Decision points were determined using CSF testing and autopsy findings as the standard.RESULTS Fujirebio and ALZpath p-tau217 had similar overall analytical and clinical performance, with distinct decision points for each assay. Based on autopsy finding, both p-tau217 assays identified individuals with AD from other neurodegenerative diseases (ALZpath AUC = 0.94, Fujirebio AUC= 0.90). The ALZpath assay detected AD pathology at milder disease stages compared to the Fujirebio assay.DISCUSSION Our study reinforces the clinical utility of plasma p-tau217 as an AD biomarker. Differences in test performance and clinical decision points suggest an assay specific diagnostic approach is required for plasma p-tau217 in clinical practice.Competing Interest StatementKH, DB, PG, and AEM are employees of Neurocode USA, Inc. Neurocode was involved in the writing and editorial support of this article. HF is a full owner of BC Neuroimmunology (BCNI) and ME and AM are employees of BCNI. GYRH discloses that he has received grants or contracts from CIHR, NIA/NIH, has been a clinical trials investigator supported by Biogen, Cassava, and Lilly, has participated in expert advisory committee supported by Biogen, Eisai, Lilly, and NovoNordisk, and is the current president of C5R (Consortium of Canadian Centres for Clinical Cognitive Research).Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethical Board at the University of British Columbia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors